for US residents only prescribing information | important safety information

(paclitaxel protein-bound particles for injectable suspension) (albumin-bound)

Terms and Conditions for the Use of ABRAXANE.com

Conditions of Use
Please read these Terms of Use and Privacy Policy carefully. By proceeding to access and use this site, you are agreeing to these terms.

All contents, including text and images, are the property of Abraxis BioScience, Inc. and/or its affiliates, and may not be downloaded, stored, reposted, modified, distributed or otherwise used except as provided herein without the express written permission of Abraxis. Abraxis reserves the right to change this site and/or the information on it at any time without notification.

Information Only
Abraxis provides the information and material on this website for general information only. This information is not intended for or as a substitute for advice, treatment or medical judgment. Abraxis does not provide, and is not intending to provide or providing advice, treatment or medical judgment. Please consult with your health care provider before using any product referenced or discussed on this site.

Use Only in and for the United States
The information on this website is intended for use only by patients, health care providers and others in and for the United States. Other countries may have laws, regulatory requirements, and medical practices that differ from those in the United States and may require references to different or additional information. Because laws, regulations, and medical practices applicable in the United States differ from those in other countries, information on this site may not be appropriate for use, and may not and should not be relied upon, outside the United States.

Copyright Notice
This site is produced by Abraxis. Abraxis hereby grants you permission to copy documents published by Abraxis on the world wide web for noncommercial use only, and only if any copy you make shall retain all copyright and other proprietary notices as on this site. Any other reproduction of any material or information on this site, or the site itself is strictly and expressly prohibited. Nothing contained herein shall confer or be construed as conferring any license or right under any patent, trademark or copyright of Abraxis, its affiliates or any third party.

No Warranty or Guarantee; Limitation
Abraxis cannot and does not guarantee the accuracy of such information. This site is provided strictly "AS IS, WHERE IS." ABRAXIS MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE WITH RESPECT TO INFORMATION CONTAINED ON THIS WEBSITE, AND HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, CREATED BY LAW, CONTRACT OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE OR NONINFRINGEMENT. IN NO EVENT SHALL ABRAXIS BE LIABLE FOR ANY DAMAGES OF ANY KIND OR NATURE, INCLUDING, WITHOUT LIMITATION, DIRECT, INDIRECT, SPECIAL (INCLUDING LOSS OF PROFIT) CONSEQUENTIAL OR INCIDENTAL DAMAGES ARISING FROM, OR IN CONNECTION WITH, THIS WEBSITE AND/OR THE INFORMATION CONTAINED HEREIN.

Links to Other Sites
Strictly as a resource to visitors of this website, Abraxis provides links to other websites, certain of which lead to resources located on servers maintained by third parties over whom Abraxis has no control. Abraxis cannot guarantee, and make no representations as to information contained on any website to which a link or reference is provided.

Prohibited Transmissions
Certain areas of this website may enable you to submit e-mails, or otherwise provide information or feedback to Abraxis or its representatives. Abraxis does not endorse, and specifically disclaims, any responsibility or liability for any content in any such submission. You may not post, submit or transmit any unlawful, threatening, libelous, defamatory, obscene, indecent, inflammatory, pornographic or profane material or any material that could constitute or encourage conduct that would be considered a criminal offense, give rise to civil liability or otherwise violate any law. You are prohibited from posting, submitting or transmitting any information which (i) infringes or may infringe any right of another, including privacy or publicity, (ii) is protected by copyright, trademark or other proprietary right, unless with the express written permission of its owner, or (iii) contains a virus, bug, worm or other harmful content. You shall be solely liable for any damage resulting from any post, submission or transmission you make.

User Information
Any "personally identifiable information" in electronic communications to the Site is governed by this website's Privacy Policy. On the other hand, any communication or material you transmit to this site by electronic mail or otherwise, including any data, questions, comments, suggestions or the like is, and will be treated as, non-confidential and non-proprietary. You understand that anything you post, submit or transmit may be used by Abraxis or representatives or its affiliates for any purpose, including reproduction, disclosure, transmission, publication, broadcast, and posting. Furthermore, Abraxis is free to use, for any purpose whatsoever and without compensation to you, any ideas, concepts, know-how, processes, or techniques contained in any communication you send, including without limitation, developing, manufacturing, marketing, and selling products and service using such ideas, concepts, know-how, processes, or techniques.

WARNING: ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

ABRAXANE therapy should not be administered to patients with metastatic breast cancer who have baseline neutrophil counts of less than 1,500 cells/mm³. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving ABRAXANE.

Note: An albumin form of paclitaxel may substantially affect a drug’s functional properties relative to those of drug in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS.

IMPORTANT SAFETY INFORMATION

The use of ABRAXANE has not been studied in patients with renal dysfunction. In the randomized controlled trial, patients were excluded for baseline serum bilirubin >1.5 mg/dL or baseline serum creatinine >2 mg/dL.

Dose adjustment is recommended for patients with moderate to severe hepatic impairment. The need for further dose adjustments in subsequent courses should be based on individual tolerance.

ABRAXANE can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with ABRAXANE. Men should be advised to not father a child while receiving treatment with ABRAXANE.

It is recommended that nursing be discontinued when receiving ABRAXANE therapy.
ABRAXANE contains albumin (human), a derivative of human blood.

Caution should be exercised when administering ABRAXANE concomitantly with known substrates or inhibitors of CYP2C8 and CYP3A4.

ABRAXANE therapy should not be administered to patients with metastatic breast cancer who have baseline neutrophil counts of less than 1,500 cells/mm³. It is recommended that frequent peripheral blood cell counts be performed on all patients receiving ABRAXANE. Patients should not be retreated with subsequent cycles of ABRAXANE until neutrophils recover to a level >1,500 cells/mm³ and platelets recover to a level >100,000 cells/mm³.

In the case of severe neutropenia (<500 cells/mm³ for 7 days or more) during a course of ABRAXANE therapy, a dose reduction for subsequent courses is recommended.

Sensory neuropathy occurs frequently with ABRAXANE.

If grade 3 sensory neuropathy develops, treatment should be withheld until resolution to grade 1 or 2 followed by a dose reduction for all subsequent courses of ABRAXANE.

Severe cardiovascular events possibly related to single-agent ABRAXANE occurred in approximately 3% of patients in the randomized trial. These events included chest pain, cardiac arrest, supraventricular tachycardia, edema, thrombosis, pulmonary thromboembolism, pulmonary embolism, and hypertension.

In the randomized metastatic breast cancer study, the most important adverse events included alopecia (90%), neutropenia (all cases 80%; severe 9%), sensory neuropathy (any symptoms 71%; severe 10%), asthenia (any 47%; severe 8%), myalgia/arthralgia (any 44%; severe 8%), anemia (all 33%; severe 1%), infections (24%), nausea (any 30%; severe 3%), vomiting (any 18%; severe 4%), diarrhea (any 27%; severe <1%), and mucositis (any 7%; severe <1%).

Other adverse reactions have included ocular/visual disturbances (any 13%; severe 1%), fluid retention (any 10%; severe 0%), hepatic dysfunction (elevations in bilirubin 7%, alkaline phosphatase 36%, AST [SGOT] 39%), renal dysfunction (any 11%; severe 1%), thrombocytopenia (any 2%; severe <1%), hypersensitivity reactions (any 4%; severe 0%), cardiovascular reactions (severe 3%), and injection site reactions (<1%). During postmarketing surveillance, rare occurrences of severe hypersensitivity reactions have been reported with ABRAXANE.

Adverse events such as fatigue, lethargy, and malaise may affect the ability to drive and use machines.

The information on this site is intended for US residents only.
ABRAXANE is a registered trademark of Abraxis BioScience, LLC.
All Abraxis BioScience, LLC. corporate names, names of services, and names of products referred to herein are trade names, service marks,
and/or trademarks that are owned by or licensed to Abraxis BioScience, its divisions or its affiliates, unless otherwise noted.
©2009 Abraxis BioScience, LLC
All Rights Reserved. AB 1395 10/09